IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
06.26.2019
EAST RUTHERFORD, N.J. – June 26, 2019 (GLOBE NEWSWIRE) – Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced three senior appointments to further support the company’s strategy to create the Contract Development and Manufacturing Organization (CDMO) of choice for small molecules within the pharmaceutical industry.
Bruno Biscaro has been appointed President, Drug Products. In this new role, he will have global responsibility for the company’s drug product business.
Mr. Biscaro has over 30 years’ experience in pharmaceutical leadership and joins Cambrex from Famar where he was President, North America. Prior to this role, he was President of Accucaps Industries and has also held numerous leadership positions for GlaxoSmithKline including his last mandate as Regional Director, Global Supply Network Program for the North American Supply Executive Team. He has a master’s degree from the University of Cambridge, UK and a Bachelor of Science degree in Industrial Engineering from Ryerson University in Toronto, Canada.
Joe Nettleton has been appointed as President, Drug Substance with responsibility for operations at the Charles City, Iowa; Karlskoga, Sweden; Wiesbaden, Germany; and Tallinn, Estonia facilities. Mr. Nettleton formally held the position of VP, US Operations and has been with Cambrex for 28 years.
Simon Edwards has been appointed as President, CDMO Sales & Marketing. He will provide customers with a single point of contact for the company’s CDMO services, as well as drive commercial activity and brand recognition for Cambrex as the leading small molecule company.
“I’m delighted to announce these appointments that underpin our strategy to be the leading small molecule company with the ability to serve customers across the entire drug lifecycle,” commented Shawn Cavanagh, EVP and Chief Operating Officer. “Our recent acquisitions of Avista and Halo align with this strategy and leverages our core strengths, while positioning us as a leading global provider of end-to-end integrated services for small molecules. These appointments play a crucial role in Cambrex delivering a wider range of services to new and existing customers.”
All positions report to Shawn Cavanagh, EVP and Chief Operating Officer.
About Cambrex
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,000 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.
Cambrex offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including oral solids, semi-solids and liquids and has the expertise to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.
For more information, please visit www.cambrex.com